Milestone Scientific Reports 46.9% Increase in Sales for the Fourth Quarter of 2017

Biotech Investing

Milestone Scientific (NYSE:MLSS) a leading developer of computerized drug delivery instruments that provide painless and precise injections, today provided a business update and announced financial results for the year ended December 31, 2017. As quoted in the press release: “We have begun to accelerate our commercial efforts around the CompuFlo® Epidural system, which was granted marketing clearance …

As quoted in the press release:

“We have begun to accelerate our commercial efforts around the CompuFlo® Epidural system, which was granted marketing clearance by the U.S. Food & Drug Administration (FDA) in 2017. Towards this end, we recently hired Sharon Smith as Executive Vice President of Global Sales and Marketing to spearhead our commercial efforts. We are now in discussions with a number of potential distributors around the world. We also look forward to having the results of our clinical trials published in industry journals later this year, which should help drive market adoption.”

Click here to read the full press release.

business update clinical trials drug delivery fda financial results nyse trials Biotech Investing